Matt Krebs

#biotech #cns #bloodbrainbarrier | Matt Krebs BBB delivery tech is entering hyperspace? In just 2 weeks: • Eli Lilly and Company + ABL Bio Inc. ($2.6B deal, IGF1R platform) • Chiesi Group + AbbVie/Aliada (rare CNS disease) • Roche + Manifold...

www.linkedin.com/posts/mattkr...

#fda #crl #rtf | Matt Krebs This one hurts. 😬 FDA slapping Biohaven with a CRL for its SCA drug--after collaborating on trial design and endpoint = OUCH!!! - Second rejection this week (see uniQure). - FDA now questioning ...

www.linkedin.com/posts/mattkr...

www.linkedin.com/posts/mattkr...

#als #parkinsons #mitochondria #neurodegeneration | Matt Krebs ⚡New Energy for ALS & Parkinson’s? Meet the other NRG. Not an energy drink. UK-based biotech advancing a novel mitochondrial approach in neurodegeneration. NRG Therapeutics closed a £50M Series B...

www.linkedin.com/posts/mattkr...

#biotech #keytruda #oncology | Matt Krebs Alteogen rides Keytruda to the Major Leagues ⚾ Just days after FDA approval of Keytruda Qlex (Merck’s subQ pembrolizumab using Alteogen’s hyaluronidase tech), the EMA backed it too. That’s two big ...

www.linkedin.com/posts/mattkr...

Is it just me, or seems like there are a bunch of “bots” leaving comments on BlueSky?

#biotech #rockinhibitor #fibrosis | Matt Krebs Remember Fraggle Rock? A scrappy bunch that, at the end of the day, got things done. They were working out of sight and underground. Well… meet AllRock Bio. Just out of stealth with a $50M Series...

www.linkedin.com/posts/mattkr...

9 to 5 and 5 to 9 on the weeken | Matt Krebs PERSONAL NOTE: What’s your ideal 9-5 / 5-9 kinda Saturday? Yesterday for me was a really good one, 'n one I hope to have more of. 🗻 Morning: - Hiked the Stanford Dish trail with my wife. ...

www.linkedin.com/posts/mattkr...

#immunology #bispecifics #harrypotter | Matt Krebs When it comes to immune modulation… 2 targets > 1? Meet Dualitas Therapeutics. A newly launched biotech using proximity biology to create bispecific antibodies that bring two cell surface targets i...

www.linkedin.com/posts/mattkr...

#venturecapital #biotech #china | Matt Krebs Scott Gottlieb Sounds Alarm on China Licensing Restrictions Why this matters for biopharma cos & financial firms: 💠 Squeezed pipeline: Chinese competition is already pushing U.S. investors to walk a...

lnkd.in/p/gVXuSQ9i

#biotech #biopharma #cardiovascular #rnai #artificialintelligence | Matt Krebs 🚀 Corsera Health, launched with $50M to prevent cardiovascular disease BEFORE it starts. Biotech legends John Maraganore (Alnylam Pharmaceuticals) and Clive Meanwell (The Medicines Company.) are bac...

www.linkedin.com/posts/mattkr...

March 2018 - HKEX Biotech Summit 2018 | Matt Krebs I have great memories being in Hong Kong in March 2018 for the first HKEX Biotech Summit with my colleague Joshua Berlin Back then, Chapter 18A was more thesis than track record. A lot has happened ...

www.linkedin.com/posts/mattkr...

#biotech #venturecapital #lifesciences | Matt Krebs 🎶 “Carolina in my mind”... with venture funds and translational science. South Carolina just launched two new VC funds via MUSC, aiming to bridge its biotech “valley of death” and punch above its wei...

www.linkedin.com/posts/mattkr...

#biotech #crossborder #biopharma | Matt Krebs Are you factoring China into your BD&L roadmap? If not, BioCentury Inc.’s latest report gives some data and insights that could change your mind: 🔹 Deals now move at "China speed". 🔹202...

www.linkedin.com/posts/mattkr...

It’s no secret that leadership teams at biotech cos are getting creative to survive--everything from partnering, fundraising, M&A, to selling off assets. | Matt Krebs It’s no secret that leadership teams at biotech cos are getting creative to survive--everything from partnering, fundraising, M&A, to selling off assets. Knowing who has dry powder isn’t enough. In...

www.linkedin.com/posts/mattkr...

Ready to take Steve Usdin’s "Master Class" on reimagining the FDA? | Matt Krebs Ready to take Steve Usdin’s "Master Class" on reimagining the FDA? 🎓⚖️ ⚠️ This isn’t for everyone ⚠️ It’s for strategic thinkers. For current (and future) thought leaders in biopharma, policy, and ...

www.linkedin.com/posts/mattkr...

True story: I was once an "illegal alien" detained in an airport 🗾 🏯 🈲 | Matt Krebs True story: I was once an "illegal alien" detained in an airport 🗾 🏯 🈲 "Illegal Alien" was my official status for about 45 mins @ KIX. It was the early 2000s. I was in KIX (Osaka Airport) heading ...

www.linkedin.com/posts/mattkr...

Can you imagine an FDA rebuilt from a blank page? | Matt Krebs Can you imagine an FDA rebuilt from a blank page? I wonder if you can? Provocative? Yes. Necessary? You be the judge. My colleague Steve Usdin’s "Back to School 2025" (BioCentury Inc.) lays out a...

www.linkedin.com/posts/mattkr...

Helped a customer last week who was finding seeming anomalies in their Series A round analysis for private biopharmas. | Matt Krebs posted on the topic | LinkedIn Helped a customer last week who was finding seeming anomalies in their Series A round analysis for private biopharmas. The problem? $100M+ rounds were throwing the numbers out of whack. They found D...

Thanks for the comment. Watch the video and it explains the anomalies in the data: www.linkedin.com/posts/mattkr...

Helped a customer last week who was finding seeming anomalies in their Series A round analysis for private biopharmas. | Matt Krebs Helped a customer last week who was finding seeming anomalies in their Series A round analysis for private biopharmas. The problem? $100M+ rounds were throwing the numbers out of whack. They found D...

1-min video on Series A financing analysis in BioCentury. www.linkedin.com/posts/mattkr...

This BioCentury Inc. | Matt Krebs This BioCentury Inc. data will surprise you? A look at private biopharma raising Seed and Series A rounds over past 9 years. https://lnkd.in/gcC-2nQZ

www.linkedin.com/posts/mattkr...

A biopharma investor told me this morning: “This 👇 is what differentiates BioCentury Inc.” | Matt Krebs posted on the topic | LinkedIn A biopharma investor told me this morning: “This 👇 is what differentiates BioCentury Inc.” They were referring to our latest coverage on quantum computing, and why it matters now for biopharma lead...

www.linkedin.com/posts/mattkr...

🎭 “Somebody stop me!” 🎭 | Matt Krebs posted on the topic | LinkedIn 🎭 “Somebody stop me!” 🎭 --masked biologics, breaking past old toxicity limits with new clinical momentum Tierney Baum, PhD (BioCentury Inc.) unveils her latest analysis on how masking platforms are ...

www.linkedin.com/posts/mattkr...

🎡 Zoltar meets predictive pharmacology? | Matt Krebs 🎡 Zoltar meets predictive pharmacology? [Full disclosure -- BIG was one of my favorite movies growing up!] My colleague Tierney Baum, PhD talks to Syndeio Biosciences on their CNS drug development...

🎡 Zoltar meets predictive pharmacology?

www.linkedin.com/posts/mattkr...

This BioCentury Inc. | Matt Krebs This BioCentury Inc. data will surprise you? A look at private biopharma raising Seed and Series A rounds over past 9 years. https://lnkd.in/gcC-2nQZ

This BioCentury Inc. data will surprise you?

A look at private biopharma raising Seed and Series A rounds over past 9 years. www.linkedin.com/posts/mattkr...

Are you seeing a flurry of activity in endometriosis? | Matt Krebs Are you seeing a flurry of activity in endometriosis? Despite this miss by Organon, I’m hearing growing investor interest. A.k.a. Endometriosis is coming up more often on calls I’m on with VCs/CVCs, ...

Monty Python fans out here? www.linkedin.com/posts/mattkr...

👀 Looking to see who is translating science into startups? | Matt Krebs 👀 Looking to see who is translating science into startups? BioCentury Inc.’s Danielle Golovin, Ph.D. spotlights several stealth-to-stage stories, including cos like: 🔹 Arzanya 🔹 Capstan Therapeutics...

www.linkedin.com/posts/mattkr...

Looking to see who is translating science into startups?

BioCentury Inc.’s Danielle Golovin, Ph.D. spotlights several stealth-to-stage stories

$2.6B VC dispute threatening to sink stealth-mode biotechs? | Matt Krebs $2.6B VC dispute threatening to sink stealth-mode biotechs? BioCentury’s Steve Usdin and Paul Bonanos unpack Apple Tree’s clash with Dmitry Rybolovlev, and what it could mean for its portfolio and th...

$2.6B VC dispute threatening to sink stealth-mode biotechs?

BioCentury’s Steve Usdin and Paul Bonanos unpack Apple Tree’s clash with Dmitry Rybolovlev, and what it could mean for its portfolio and the broader biotech ecosystem.

📄 Full analysis 👇 👇 👇
www.linkedin.com/posts/mattkr...

PERSONAL NOTE: Any wiffleball fans out there? | Matt Krebs PERSONAL NOTE: Any wiffleball fans out there? Ever get a box of old photos that took you back to your childhood? Flood of memories poor in? Recently, I came across the pic of me and my bro (the pi...

Wiffleball anyone? www.linkedin.com/posts/mattkr...

👇👇👇 | Matt Krebs 👇👇👇

From my @biocentury.bsky.social colleague: www.linkedin.com/posts/mattkr...